Prevacus Announces the Addition of Key Individuals to its Sports Advisory Board

TALLAHASSEE, Fla., Feb. 22, 2017 -- Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other neurological disorders; today announced the addition of Steve Mariucci, Eddie DeBartolo Jr., Matt Hasselbeck and Warren Moon to its sports advisory board.

"I am delighted to have the support of these outstanding individuals," said Dr. Jake VanLandingham, CEO of Prevacus, "Their experience and leadership coupled with the scientific excellence that we have cultivated here at Prevacus will help us develop a pathway forward for quality treatment of concussions in our athletes, military as well as individuals that sustain a fall or have a motor vehicle accident"

The new additions join previously added board members including Brett Favre, Jay Saldi, Roger Staubach, Leigh Steinberg and James ‘Bus’ Cook.

About Steve Mariucci
Steve "Mooch" Mariucci is the former Head Coach for the NFL with both the San Francisco 49ers and Detroit Lions. He was also Brett Favre’s Quarterback coach when he arrived in Green Bay. Mooch is on the NFL Safety and Rules Advisory Board.

About Eddie DeBartolo Jr.
Mr. DeBartolo is the former owner of the San Francisco 49ers where he won 5 Super Bowls. He has had immense success in Real Estate and as a Philanthropist.

About Matt Hasselbeck
Matt is a former NFL Quarterback with most of his playing days spent with the Seattle Seahawks. He is currently a member of the NFL ESPN analyst team. Matt is currently an executive member of the NFLPA union and works tirelessly on behalf of the players.

About Warren Moon
Warren Moon is a Hall of Fame NFL Quarterback and is currently a commentator for the Seahawks radio network. Mr. Moon co-founded Sports 1 Marketing in 2010.

About Prevacus
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first development candidate (PRV-002) represents a breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, ischemic injury and oxidative stress.

About Concussion
A concussion is a type of traumatic brain injury caused by a significant force to the head or upper body causing the brain to shake inside the skull. The injury is defined as a concussion when it causes a change in mental status such as amnesia, disorientation, mental fogginess, confusion, nausea/vomiting, blurred vision, headache, balance deficits or loss of consciousness. There are 21 symptoms demonstrated to be associated with concussion. Loss of consciousness does not indicate injury severity. Because no two concussions are exactly alike, effects and recovery are sometimes difficult to assess. Therefore the condition requires a compound that can work to reduce multiple pathological issues.

About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid administered through the nasal cavity. PRV-002 carries with it equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, future financial results, including operating expenses and cash position, pursuit of strategic options and pursuit of research and clinical development programs. Risks that contribute to the uncertain nature of the forward-looking statements include: we expect to incur losses for the foreseeable future and will need additional funds to finance our operations; our operating results fluctuate significantly; our estimates regarding our ability to initiate and/or complete our clinical trials and the timing and expense of these trials may not be accurate; enrollment in our clinical trials may be delayed; our clinical trials may not demonstrate the efficacy and safety of our product candidates; we may not be able to manufacture our product candidates on a commercial scale in a timely or cost-efficient manner; our estimates regarding expenses and capital requirements may not be accurate; regulatory developments in the United States and foreign countries may adversely affect our operations or prospects; we must obtain and maintain intellectual property protection for our product candidates; the loss of key scientific or management personnel could adversely affect our operations. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact
CG Capital
877.889.1972
[email protected]
http://www.cg.capital